AzTrials
AzTrials

Body WeightNCT02064205

Appetite Suppression Trial With Polydextrose

A study testing 12.5 g polydextrose and glucose syrup in people with Body Weight and Non-restrained Eaters, run by W.J. Pasman at 1 site in Netherlands.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Overweight and obesity are a global epidemic, which causes a rapid increase in the frequency of diabetes and cardiovascular diseases. Food ingredients that influence the mechanisms that regulate satiety may play a role in weight management. Read more about this study

Who is it for?
Ages 20 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Body Weight, Non-restrained Eaters
What is being tested?
12.5 g polydextrose and glucose syrup
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
32 participants
Where
1 siteNetherlands
Study dates
May 2014to Dec 2014
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy, female participants aged 20-45 years inclusive
  • BMI: 20-30 kg/m2 inclusive
  • Written consent regarding participation after full information regarding all details of the study
  • Normal Dutch eating habits (consuming mostly three main meals per day; used to eat bread for lunch)

Who cannot join

  • Pregnancy
  • On-going or recent treatment for diabetes, hypertension, coronary heart disease, psychiatric conditions, inflammatory chronic disease - rheumatoid arthritis, Crohn Disease, ulcerous colitis, chronic constipation, eating disorders, or any disease condition which interferes with ADME of the investigational product
  • Reported postmenopausal
  • Having menstruation problems, e.g. PCOS
  • Reported to be on a slimming diet or other dietary treatment (currently or during last two months, like vegetarian diet, lactose restricted diet etc.)
  • Aversion towards products (yoghurt) provided in the study
Show all 18Show fewer
  • On-going use of any slimming preparations
  • Any kind of dysfunction of digestive tract, food allergy, chronic constipation, recent/actual gastroenteritis
  • Restrained eaters (score DEBQ >3.4)
  • Participants consuming more than 23g of dietary fiber per day - P75 according to the Dutch National Food Consumption Survey - (as assessed with a general short questionnaire which gives estimation on the fiber intake. Exact fiber intake will not be calculated)
  • Smoker in the last 3 months
  • Heavy coffee drinkers (more than 6 cups a day)
  • High level of physical activity: Participants who perform more than 3 hours of intense training/sport activity per week (this will not include normal cycling transport)
  • Heavy alcohol consumers, no more than 14 units per week (1 unit represents 1 standard glass/portion of alcohol, independent of the type of alcoholic drink).
  • Remark:
  • When enough subjects are eligible (> 32), the women with the highest BMI will be selected to participate. At least 50% of the subjects will have a BMI ranging of 25-30. Also at least 50% of the women will be in the age range of 25-45 years. When more than 32 subjects are eligible the eldest subjects will be included.
  • With respect to eligibility of the subjects:
  • the BMI criterion always comes for age criterion, meaning that overweight is stressed to be of more importance for this study than age. Overweight will always come first, even when already > 50% of the women with a BMI 25-30 have been included. In this way the overweight group of women will be studied as much as possible.

Trial locations and contacts

1 site in 1 country.

Netherlands1 site
  • QPS

    Groningen, 9713AG

Other trials in Netherlands

About this study

Official title: A Double Blind, Placebo Controlled, Randomized, Cross-over Study to Assess the Effects of Polydextrose on Appetite Suppression and Its Mechanisms of Action in Healthy Women With a Normal Weight and Overweight Female Participants.

Overweight and obesity are a global epidemic, which causes a rapid increase in the frequency of diabetes and cardiovascular diseases. Food ingredients that influence the mechanisms that regulate satiety may play a role in weight management. Suppression of appetite may reduce energy intake, which in return may lead to body weight reduction. This study aims to verify the appetite suppressive effect of polydextrose in comparison to a placebo in normal weight and overweight women.

Read the detailed description

Polydextrose is a well-tolerated, low calorie glucose polymer (4kJ/g) that can be easily incorporated into various food applications to replace sugar and fat (Auerbach et al., 2007). Polydextrose is poorly digested in the upper gastrointestinal tract and therefore shows fiber-like properties. The addition of polydextrose to foods may increase the satiating properties of foods.

Previous studies have shown that:

  • Consuming polydextrose-containing preloads (6.25 - 25.0 g polydextrose) resulted in a significant lower energy intake at lunch compared to the control (Astbury et al., 2013; Ranawana et al., 2013; Hull et al., 2012; King et al., 2005).
  • Polydextrose is able to modify appetite ratings at low (6.25 - 12.5 g polydextrose) (Hull et al., 2012) and high doses (56.7 g/d) (Konings et al., 2013).
  • Polydextrose (15.0 g) induced enhanced GLP-1 response after a high-fat meal in obese participants (Tiihonen et al., 2012).

Therefore, it is hypothesized that with the consumption of 12.5 g polydextrose as compared with the placebo, appetite will be suppressed, resulting in:

  • a lower consumption at lunch (energy intake at lunch)
  • change in appetite scores (VAS)
  • change in satiety hormones (CCK, PYY, GLP-1, ghrelin)
  • change in glucose and insulin
  • change in stomach emptying rate
  • change in gastric wellbeing
Being tested
12.5 g polydextrose, glucose syrup
Keywords
pre-load, satiety, energy intake, appetite
Medical subject headings
Body Weight

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 12.5 g polydextroseDietary supplement

    Also called Litesse®Ultra TM

    Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.

  • glucose syrupDietary supplement

    Glucose syrup is used a control product for the polydextrose

Study groups in NCT02064205
Study groupRoleWhat they receive
polydextrose or glucose syrup at breakfastActive comparatorBreakfast with pre-load four hours before lunch
Receives: Dietary Supplement: 12.5 g polydextrose; Dietary Supplement: glucose syrup
Pre-load with yogurt and polydextrose or glucose laterPlacebo comparatorBreakfast without pre-load. Pre-load with yogurt provided 1.5h before lunch.
Receives: Dietary Supplement: 12.5 g polydextrose; Dietary Supplement: glucose syrup

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Energy Intake at an ad Libitum Lunch on a Test-day in Normal Weight and Overweight Women.

    Yogurt with a polydextrose (fiber with satiating effect) is consumed in the morning with breakfast or later in the morning. The satiating effect of the addition of polydextrose is tested on the amount of food consumed with lunch four hours or 1.5h later.

    Measured: Four hours or 1.5 hour after consumption of a pre-load at up to day 22

Secondary outcomes (2)
  1. The Appetite Suppressive Effect of Polydextrose During Meal Consumption (Satiation) and Satiety (After Food Consumption)

    The appetite suppressive effect of polydextrose measured with Visual Analogue rating Scales (VAS). The AUCs were calculated for the scores obtained before - first score after meal intake (satiation) and for score after meal till start of next meal (in between meals, satiety). The VAS scores ranged from 0-100 for hunger and fullness (HUNGER: 0 = no hunger , 100 = very hungry; FULNESS: 0 = not full, 100 = very full)

    Measured: one day

  2. Evaluate Effect of Pre-load on Satiety Hormones in Normal Weight and Overweight Women.

    The satiety hormones CCK, GLP-1, ghrelin and PYY are measured before (t=0) and after breakfast consumption (at t=30, 60, 90, 150, 240) . This is done on day 01, day 08, day 15 and day 22 with at least four days wash-out in-between.

    The satiety hormones were only measured in the conditions when the pre-load was given with breakfast (condition A and B).

    Area under the curves were calculated of the time curves.

    Measured: Four hour curves (t=0, 30, 60, 90, 150 and 240 min) of day 01, day 08, day 15 and day 22.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Feb 2014 (estimated)
  2. Study startMay 2014
  3. Primary completionOct 2014
  4. Study completionDec 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Crossover
Model description
Breakfast meal with or without polydextrose
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
32 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02064205
Sponsor's protocol ID
JZ PDX Satiety
Other IDs
WM-01-2014
Status last verified
May 2022
First submitted
11 Feb 2014
Last updated
6 Jun 2022
Data monitoring committee
No

Publications

  • Ibarra A, Olli K, Pasman W, Hendriks H, Alhoniemi E, Raza GS, Herzig KH, Tiihonen K. Effects of polydextrose with breakfast or with a midmorning preload on food intake and other appetite-related parameters in healthy normal-weight and overweight females: An acute, randomized, double-blind, placebo-controlled, and crossover study. Appetite. 2017 Mar 1;110:15-24. doi: 10.1016/j.appet.2016.12.002. Epub 2016 Dec 2.

    PubMed 27916475

Questions about this trial

What is this clinical trial studying?

A study testing 12.5 g polydextrose and glucose syrup in people with Body Weight and Non-restrained Eaters, run by W.J. Pasman at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 6 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 27 Jul 2016). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Energy Intake at an ad Libitum Lunch on a Test-day in Normal Weight and Overweight Women. (time frame: Four hours or 1.5 hour after consumption of a pre-load at up to day 22). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02064205, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jun 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in